Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The study is looking at the efficacy of subcutaneously administrated denosumab 60 mg every 6
months versus placebo after 3 years, by analyze of lumbar spine bone mineral density (BMD) in
systemic mastocytosis.
Investigators hypothesize that use of denosumab subcutaneously in patients with osteoporosis
related to systemic mastocytosis is effective and safe to improve bone mineral density and
prevent new bone events, based on targeted specific RANKL secretion by mast cells and short
half-life of denosumab.